Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Dowdy DW, Theron G, Tornheim JA, Warren R, Kendall EA.

Clin Infect Dis. 2017 Oct 1;65(7):1206-1211. doi: 10.1093/cid/cix486.

PMID:
29554229
2.

Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.

Lv L, Li T, Xu K, Shi P, He B, Kong W, Wang J, Sun J.

Infect Drug Resist. 2018 Jan 23;11:147-154. doi: 10.2147/IDR.S153499. eCollection 2018.

3.

Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy.

Tousif S, Singh DK, Mukherjee S, Ahmad S, Arya R, Nanda R, Ranganathan A, Bhattacharyya M, Van Kaer L, Kar SK, Das G.

Front Immunol. 2017 Jun 30;8:739. doi: 10.3389/fimmu.2017.00739. eCollection 2017.

4.

The Rate of Drug-Resistant Tuberculosis in Korean Children and Adolescents Since 2007.

Kim HJ, Yoon HH, Eun BW, Ahn Y, Ryoo S, Kim HJ.

J Korean Med Sci. 2017 Jun;32(6):954-960. doi: 10.3346/jkms.2017.32.6.954.

5.

Primary Extrapulmonary Extensively Drug Resistant Tuberculosis of the Hip in an Immunocompetent Female-A Case Report.

Yadav S, Rawal G.

J Clin Diagn Res. 2017 Jan;11(1):LD01-LD03. doi: 10.7860/JCDR/2017/23401.9141. Epub 2017 Jan 1.

6.

Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.

Yin QQ, Jiao WW, Li QJ, Xu F, Li JQ, Sun L, Li YJ, Huang HR, Shen AD.

BMC Microbiol. 2016 May 12;16:85. doi: 10.1186/s12866-016-0699-2.

7.

Primary Extrapulmonary Multidrug-Resistant Tuberculosis of the Sternum without HIV Infection.

Yadav S, Rawal G.

J Clin Diagn Res. 2016 Jan;10(1):RD01-3. doi: 10.7860/JCDR/2016/15395.7096. Epub 2016 Jan 1.

8.

Prevalence and Predictors of Self-Medication with Antibiotics in Al Wazarat Health Center, Riyadh City, KSA.

Al Rasheed A, Yagoub U, Alkhashan H, Abdelhay O, Alawwad A, Al Aboud A, Al Battal S.

Biomed Res Int. 2016;2016:3916874. doi: 10.1155/2016/3916874. Epub 2016 Jan 5.

9.

Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar.

Tripathy S, Kumar R, Singh SD.

J Clin Diagn Res. 2015 Nov;9(11):LC09-12. doi: 10.7860/JCDR/2015/14024.6793. Epub 2015 Nov 1.

10.

The challenge of sustaining effectiveness over time: the case of the global network to stop tuberculosis.

Quissell K, Walt G.

Health Policy Plan. 2016 Apr;31 Suppl 1:i17-32. doi: 10.1093/heapol/czv035. Epub 2015 Aug 17.

11.

Epidemiological Characterization of Drug Resistance among Mycobacterium tuberculosis Isolated from Patients in Northeast of Iran during 2012-2013.

Tavanaee Sani A, Shakiba A, Salehi M, Bahrami Taghanaki HR, Ayati Fard SF, Ghazvini K.

Biomed Res Int. 2015;2015:747085. doi: 10.1155/2015/747085. Epub 2015 May 3.

12.

Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.

Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, Gomez GB.

BMC Public Health. 2015 Mar 25;15:291. doi: 10.1186/s12889-015-1614-8. Review.

13.

A prospective study of tuberculosis drug susceptibility in sabah, malaysia, and an algorithm for management of isoniazid resistance.

Rashid Ali MR, Parameswaran U, William T, Bird E, Wilkes CS, Lee WK, Yeo TW, Anstey NM, Ralph AP.

J Trop Med. 2015;2015:261925. doi: 10.1155/2015/261925. Epub 2015 Mar 9.

14.

Drug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional survey.

Abouyannis M, Dacombe R, Dambe I, Mpunga J, Faragher B, Gausi F, Ndhlovu H, Kachiza C, Suarez P, Mundy C, Banda HT, Nyasulu I, Squire SB.

Bull World Health Organ. 2014 Nov 1;92(11):798-806. doi: 10.2471/BLT.13.126532. Epub 2014 Sep 18.

15.

Global epidemiology of tuberculosis.

Glaziou P, Sismanidis C, Floyd K, Raviglione M.

Cold Spring Harb Perspect Med. 2014 Oct 30;5(2):a017798. doi: 10.1101/cshperspect.a017798. Review.

16.

Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection.

Tousif S, Singh DK, Ahmad S, Moodley P, Bhattacharyya M, Van Kaer L, Das G.

J Biol Chem. 2014 Oct 31;289(44):30190-5. doi: 10.1074/jbc.C114.598946. Epub 2014 Sep 8.

17.

Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa.

Dlamini-Mvelase NR, Werner L, Phili R, Cele LP, Mlisana KP.

BMC Infect Dis. 2014 Aug 16;14:442. doi: 10.1186/1471-2334-14-442.

18.

Are we doing enough to stem the tide of acquired MDR-TB in countries with high TB burden? Results of a mixed method study in Chongqing, China.

Li Y, Ehiri J, Oren E, Hu D, Luo X, Liu Y, Li D, Wang Q.

PLoS One. 2014 Feb 5;9(2):e88330. doi: 10.1371/journal.pone.0088330. eCollection 2014.

19.

Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.

Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, Kuo CH, Chang PJ, Kuo HP.

PLoS One. 2014 Jan 22;9(1):e86316. doi: 10.1371/journal.pone.0086316. eCollection 2014.

20.

Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.

Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K.

PLoS One. 2013 Nov 6;8(11):e77712. doi: 10.1371/journal.pone.0077712. eCollection 2013.

Supplemental Content

Support Center